Disturbed one-carbon metabolism causing adverse reproductive outcomes in mice is associated with altered expression of apolipoprotein AI and inflammatory mediators: PPARα, Interferon-γ, and interleukin-10

Journal of Nutrition

Volumn 142, Issue 3, 2012, Pages 411-418

  Mikael, Leonie G ^a   Pancer, Jill ^a   Wu, Qing ^a   Rozen, Rima ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN A1; GAMMA INTERFERON; INTERLEUKIN 10; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBON METABOLISM; CONTROLLED STUDY; DISTURBED ONE CARBON METABOLISM; DNA METHYLATION; EMBRYO; ENZYME DEFICIENCY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; LIVER LEVEL; METABOLIC DISORDER; MOUSE; NONHUMAN; PLACENTA; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PROMOTER REGION; PROTEIN EXPRESSION; VITAMIN DEFICIENCY;

ANIMALS; APOLIPOPROTEIN A-I; CHOLINE DEFICIENCY; DNA METHYLATION; FEMALE; GENE EXPRESSION; HOMOCYSTEINE; HOMOCYSTINURIA; HYPERHOMOCYSTEINEMIA; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN-10; LIVER; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MUSCLE SPASTICITY; PLACENTA; PPAR ALPHA; PREGNANCY; PREGNANCY COMPLICATIONS; PROMOTER REGIONS, GENETIC; PSYCHOTIC DISORDERS; RNA, MESSENGER;

MUS;

EID: 84858215555     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.111.151753     Document Type: Article

References (60)

1. Chan J, Deng L, Mikael LG, Yan J, Pickell L, Wu Q, Caudill MA, Rozen R. Low dietary choline and low dietary riboflavin during pregnancy influence reproductive outcomes and heart development in mice. Am J Clin Nutr. 2010;91:1035-43.
2. Albright CD, Tsai A, Friedrich C, Mar M, Zeisel S. Choline availability alters embryonic development of the hippocampus and septum in the rat. Brain Res Dev Brain Res. 1999;113:13-20.
3. Fisher MC, Zeisel S, Mar M, Sadler T. Inhibitors of choline uptake and metabolism cause developmental abnormalities in neurulating mouse embryos. Teratology. 2001;64:114-22.
4. Schwahn BC, Chen Z, Laryea MD, Wenderl U, Lussier-Cacan S, Genest J Jr, Mar MH, Zeisel SH, Castro C, Garrow T, et al. Homocysteinebetaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency. FASEB J. 2003;17:512-4.
5. Li D, Pickell L, Liu Y, Wu Q, Cohn JS, Rozen R. Maternal methylenetetrahydrofolate reductase deficiency and low dietary folate lead to adverse reproductive outcomes and congenital heart defects in mice. Am J Clin Nutr. 2005;82:188-95.
6. Pickell L, Li D, Brown K, Mikael LG, Wang XL, Wu Q, Luo L, Jerome-Majewska L, Rozen R. Methylenetetrahydrofolate reductase deficiency and low dietary folate increase embryonic delay and placental abnormalities in mice. Birth Defects Res A Clin Mol Teratol. 2009;85: 531-41.
7. Havel RJ. Introduction: structure and metabolism of plasma lipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 7th ed. New York: McGraw-Hill; 1995. p. 1841-51.
8. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming. Circulation. 2001;104:2376-83.
9. McConihay JA, Honkomp AM, Granholm NA, Woollett LA. Maternal high density lipoproteins affect fetal mass and extra-embryonic fetal tissue sterol metabolism in the mouse. J Lipid Res. 2000;41:424-32.
10. Herrera E, Amusquivar E, Lopez-Soldado I, Ortega H. Maternal lipid metabolism and placental transfer. Horm Res. 2006;65:59-64.
11. Mikael LG, Genest J Jr, Rozen R. Elevated homocysteine reduces Apolipoprotein A-I expression in Hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res. 2006;98:564-71.
12. Mikael LG, Rozen R. Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF-kB/ iNOS. Cardiovasc Res. 2008; 80:151-8.
13. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999;131:363-75.
14. Dodds L, Fell DB, Dooley KC, Armson BA, Allen AC, Nassar BA, Perkins S, Joseph KS. Effect of homocysteine concentration in early pregnancy on gestational hypertensive disorders and other pregnancy outcomes. Clin Chem. 2008;54:326-34.
15. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, Monsen ALB, Ueland PM. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine Study. Am J Clin Nutr. 2000;71:962-8.
16. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews R, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-3.
17. Chen Z, Karaplis AC, Ackerman SL, Pogribny IP, Melnyk S, Lussier-Cacan S, Chen MF, Pai A, John SW, Smith RS, et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet. 2001;10:433-43.
18. Mikael LG, Wang XL, Wu Q, Jiang H, Maclean KN, Rozen R. Hyperhomocysteinemia is associated with hypertriglyceridemia in mice with methylenetetrahydrofolate reductase deficiency. Mol Genet Metab. 2009;98:187-94.
19. Furlaneto CJ, Ribeiro FP, Hatanaka E, Souza GM, Cassatella MA, Campa A. Apolipoproteins A-I and A-II downregulate neutrophil functions. Lipids. 2002;37:925-8.
20. Suzuki M, Pritchard DK, Becker L, Hoofnagle AN, Tanimura N, Bammler TK, Beyer RP, Bumgarner R, Vaisar T, de Beer MC, et al. High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide. Circulation. 2010;122:1919-27.
21. Dong M, He J, Wang Z, Xie X, Wang H. Placental imbalance of Th1-and Th2-type cytokines in preeclampsia. Acta Obstet Gynecol Scand. 2005;84:788-93.
22. Yessoufou A, Hichami A, Besnard P, Moutairou K, Khan NA. Peroxisome proliferator-activated receptor a deficiency increases the risk of maternal abortion and neonatal mortality in murine pregnancy with or without diabetes mellitus: modulation of T cell differentiation. Endocrinology. 2006;147:4410-8.
23. Hewitt DP, Mark PJ, Waddell BJ. Placental expression of peroxisome proliferator-activated receptors in rat pregnancy and the effect of increased glucocorticoid exposure. Biol Reprod. 2006;74:23-8.
24. Banerjee S, Smallwood A, Moorhead J, Chambers AE, Papageorghiou A, Campbell S, Nicolaides K. Placental expression of interferon-g (IFN-γ) and its receptor IFN-γR2 fail to switch from early hypoxic to late normotensive development in preeclampsia. J Clin Endocrinol Metab. 2005;90:944-52.
25. De Lemos MA. How your mother tolerated you for nine months. BioTeach J. 2003;1:27-9.
26. Szekeres-Bartho J, Halasz M, Palkovics T. Progesterone in pregnancy; receptor-ligand interaction and signaling pathways. J Reprod Immunol. 2009;83:60-4.
27. Bazzoni F, Tamassia N, Rossato M, Cassatella MA. Understanding the molecular mechanisms of the multifaceted IL-10-mediated anti-inflammatory response: lessons from neutrophils. Eur J Immunol. 2010;40: 2360-8.
28. Thompson PW, Bayliffe AI, Warren AP, Lamb JR. Interleukin-10 is upregulated by nanomolar rosiglitazone treatment of mature dendritic cells and human CD4+ T cells. Cytokine. 2007;39:184-91.
29. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993;123:1939-51.
30. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, Cantor CR, Filed JK, van den Boom D. Quantitative highthroughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA. 2005;102: 15785-90.
31. Lillycrop KA, Phillips ES, Torrens C, Hanson MA, Jackson AA, Burdge GC. Feeding pregnant rats a protein-restricted diet persistently alters the methylation of specific cytosines in the hepatic PPAR alpha promoter of the offspring. Br J Nutr. 2008;100:278-82.
32. Lillycrop KA, Phillips ES, Jackson AA, Hanson MA, Burdge GC. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. J Nutr. 2005;135:1382-6.
33. Burdge GC, Slater-Jefferies J, Torrens C, Phillips ES, Hanson MA, Lillycrop KA. Dietary protein restriction of pregnant rats in the F0 generation induces altered methylation of hepatic gene promoters in the adult male offspring in the F1 and F2 generations. Br J Nutr. 2007;97: 435-9.
34. Michalik L, Devergne B, Dreyer C, Gavillet M, Laurini RN, Wahli W. PPAR expression and function during vertebrate development. Int J Dev Biol. 2002;46:105-14.
35. Syto R, Murgolo NJ, Braswell EH, Mui P, Huang E, Windsor WT. Structural and biological stability of the human interleukin 10 homodimer. Biochemistry. 1998;37:16943-51.
36. Josephson K, DiGiacomo R, Indelicato SR, Iyo AH, Nagabhushan TL, Parker MH, Walter MR. Design and analysis of an engineered human interleukin-10 monomer. J Biol Chem. 2000;275:13552-7.
37. Bortesi L, Rossato M, Schuster F, Raven N, Stadlmann J, Avesani L, Falorni A, Bazzoni F, Bock R, Schillberg S, et al. Viral and murine interleukin-10 are correctly processed and retain their biological activity when produced in tobacco. BMC Biotechnol. 2009;9:22-34.
38. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol. 1993;11:165-90.
39. Fitzgerald KA, O'neill LAJ, Gearing AJH, Callard RE, editors. The cytokine factsbook. 2nd ed. San Diego: Academic Press; 2001.
40. Knopp RH, Warth MR, Charles D, Childs M, Li JR, Mabuchi H, Van Allen MI. Lipoprotein metabolism in pregnancy, fat transport to the fetus, and the effects of diabetes. Biol Neonate. 1986;50:297-317.
41. Baroukh N, Lopeza CE, Saleh MC, Recalde D, Vergnes L, Ostos MA, Fiette L, Fruchart J-C, Castro G, Zakin MM, et al. Expression and secretion of human apolipoprotein A-I in the heart. FEBS Lett. 2004;557:39-44.
42. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol. 2001;169:453-9.
43. Rees WD, McNeil CJ, Maloney CA. The roles of PPARs in the fetal origins of metabolic health and disease. PPAR Res. 2008;2008:459030.
44. Asami-Miyagishi R, Iseki S, Usui M, Uchida K, Kubo H, Morita I. Expression and function of PPARgamma in rat placental development. Biochem Biophys Res Commun. 2004;315:497-501.
45. Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss JF III, Petraglia F. Inflammation and pregnancy. Reprod Sci. 2009;16:206-15.
46. Curry AE, Vogel I, Drews C, Shcendel D, Skogstrand K, Flanders WD, Hougaard D, Olsen J, Thorsen P. Mid-pregnancy maternal plasma levels of interleukin-2, 6, and 12, tumor necrosis factor-alpha, interferon gamma, and granulocyte-macrophage colony-stimulating factor and spontaneous preterm delivery. Acta Obstet Gynecol Scand. 2007;86:1103-10.
47. Makris A, Xu B, Yu B, Thornton C, Hennessy A. Placental deficiency of interleukin-10 (IL-10) in preeclampsia and its relationship to an IL10 promoter polymorphism. Placenta. 2006;27:445-51.
48. Kovacheva VP, Mellott TJ, Davison JM, Wagner N, Lopez-Coviella I, Schnitzler AC, Blusztajn J. Gestational choline deficiency causes global and Igf2 gene DNA hypermethylation by up-regulation of Dnmt1 expression. J Biol Chem. 2007;282:31777-88.
49. Bayarsaihan D. Epigenetic mechanisms in inflammation. J Dent Res. 2011;90:9-17.
50. Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev. 2002;12:198-209.
51. Mehedint MG, Niculescu MD, Craciunescu CN, Zeisel S. Choline deficiency alters global histone methylation and epigenetic marking at the Re1 site of the calbindin 1 gene. FASEB J. 2010;24:184-95.
52. Davison JM, Mellott TJ, Kovacheva VP, Blusztajn J. Gestational choline supply regulates methylation of histone H3, expression of histone methyltransferases G9a (Kmt1c) and Suv39h1 (Kmt1a), and DNA methylation of their genes in rat fetal liver and brain. J Biol Chem. 2009;284:1982-9.
53. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009;41: 178-86.
54. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor a negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kB and AP-1. J Biol Chem. 1999;274:32048-54.
55. Racke MK, Gocke AR, Muir M, Diab A, Drew PD, Lovett-Racke AE. Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J Nutr. 2006;136:700-3.
56. D'Andrea A, Aste-Amezaga M, Valiante N, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gammaproduction by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med. 1993;178:1041-8.
57. Schroecksnadel K, Frick B, Winkler C, Fuchs D. Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol. 2006;4:205-13.
58. Schroecksnadel K, Frick B, Wirleitner B, Winkler C, Schennach H, Fuchs D. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol. 2004;5:107-18.
59. Wu JT. Circulating homocysteine is an inflammation marker and a risk factor of life-threatening inflammatory diseases. J Biomed Lab Sci. 2007;19:107-11.
60. Marcolin E, Forgiarini LF, Tieppo J, Dias AS, Freitas LA, Marroni N. Methionine- and choline-deficient diet induces hepatic changes characteristic of non-alcoholic steatohepatitis. Arq Gastroenterol. 2011;48: 72-9.